PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2005 September; 6(3): E487–E494.
Published online 2005 October 24. doi:  10.1208/pt060361
PMCID: PMC2750395

Preparation, in vitro release, in vivo absorption and biocompatibility studies of insulin-loaded microspheres in rabbits

Abstract

The purpose of this study was to develop a single-dose insulin delivery system based on poly (lactide-co-glycolide) (PLGA) microspheres to provide basal insulin level for a prolonged period. Insulin-loaded PLGA microspheres were prepared by water-in-oil-in-water double emulsion (batch A) and solid-in0oil-in-water emulsion (batch B) methods. Microspheres were characterized for physical characteristics and in vitro release. In vivo absorption of insulin and biocompatibility of insulin-loaded PLGA microspheres were performed in diabetic New Zealand white rabbits. Light and transmission electron microscopy were performed on the skin tissues excised from microspheres injected sites in order to study the biocompatibility. The burst release of insulin was high (47%) from batch B and low (5%) from batch A. Therefore, we mixed microspheres of batch A and B in ratio of 3[ratio] w/w, which produced desirable in vitro release profile. In vivo absorption study showed that insulin-loaded microspheres provided a serum insulin level of 20–40 μU/ml up to 40 days. Biocompatibility study provided evidence of normal inflammatory and foreign body reactions, which were characterized by the presence of macrophages, fibroblasts and foreign body giant cells. Neither necrosis nor tissue damage was identified. At the end of 12 weeks, no distinct histological differences were observed in comparison to the control tissue samples. In conclusion, insulin-loaded PLGA microspheres controlled the in vivo absorption of insulin to maintain the basal insulin level for longer period and the delivery system was biocompatible.

Keywords: PLGA, microspheres, insulin, in vivo absorption, biocompatibility

Full Text

The Full Text of this article is available as a PDF (569K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Steil CF. Diatetes mellitus. In: DiPiro JT, Talbert RL, Yee GC, editors. Pharmacotherapy: A pathophysiologic approach. 4th ed. Stamford, CT: Appleton & Lange; 1999. pp. 1219–1243.
2. Galloway JA, Chance RE. Improving insulin therapy: achievements and challenges. Horm Metab Res. 1994;26:591–598. doi: 10.1055/s-2007-1001766. [PubMed] [Cross Ref]
3. White J, Campbell RD. Diabetes mellitus. In: Herfindal ET, Gourly DR, editors. Textbook of therapeutics: drug and disease management. Baltimore, MD: Williams & Wilkins; 1996. pp. 357–386.
4. Riddle MC. Timely initiation of basal insulin. Am J Med. 2004;116:3S–9S. doi: 10.1016/j.amjmed.2003.12.003. [PubMed] [Cross Ref]
5. LeRoith D, Levetan CS, Hirsch IB, Riddle MC. Type 2 diabetes: the role of basal insulin therapy. J Fam Pract. 2004;53:215–222. [PubMed]
6. Jiang G, Qiu W, DeLuca PP. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres. Pharm Res. 2003;20:452–459. doi: 10.1023/A:1022668507748. [PubMed] [Cross Ref]
7. Ziats NP, Miller KM, Anderson JM. In vitro and in vivo interactions of cells with biomaterials. Biomaterials. 1988;9:5–13. doi: 10.1016/0142-9612(88)90063-4. [PubMed] [Cross Ref]
8. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of poly lactic acid/polyglycolic acid copolymers. Biomaterials. 1996;17:93–102. doi: 10.1016/0142-9612(96)85754-1. [PubMed] [Cross Ref]
9. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5–24. doi: 10.1016/S0169-409X(97)00048-3. [PubMed] [Cross Ref]
10. Pariente JL, Kim BS, Atala A. In vitro biocompatibility assessment of naturally derived and synthetic biomaterials using normal human urothelial cells. J Biomed Mater Res. 2001;55:33–39. doi: 10.1002/1097-4636(200104)55:1<33::AID-JBM50>3.0.CO;2-7. [PubMed] [Cross Ref]
11. Ike O, Shimizu Y, Wada R, Hyon SH, Ikada Y. Controlled cisplatin delivery system using poly(D,L-lactic acid) Biomaterials. 1992;13:230–234. doi: 10.1016/0142-9612(92)90189-U. [PubMed] [Cross Ref]
12. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76–85. doi: 10.1016/0003-2697(85)90442-7. [PubMed] [Cross Ref]
13. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22:158–161. doi: 10.1136/jcp.22.2.158. [PMC free article] [PubMed] [Cross Ref]
14. Morgan CR, Lazarow A. Immunoassay of insulin using a two-antibody system. Proc Soc Exp Biol Med. 1962;110:29–32. [PubMed]
15. Ravivarapu HB, Burton K, DeLuca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm. 2000;50:263–270. doi: 10.1016/S0939-6411(00)00099-0. [PubMed] [Cross Ref]
16. Takenaga M, Yamaguchi Y, Kitagawa A, Ogawa Y, Mizushima Y, Igarashi R. A novel insulin formulation can keep providing steady levels of insulin for much longer periods in-vivo. J Pharm Pharmacol. 2002;54:1189–1194. doi: 10.1211/002235702320402026. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists